Storys zum Thema Pharmaindustrie
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- Ein Dokumentmehr
Press release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
Ein DokumentmehrPress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
Ein Dokumentmehr- 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
Ein Dokumentmehr - 2
Press Release: Aurubis subsidiary RETORTE expanding selenium production for profitable growth markets
Ein Dokumentmehr Gerresheimer with a good start to 2023 financial year: Again double-digit growth in revenues and Adjusted EBITDA
Düsseldorf (ots) - - First-quarter revenues grew organically by 21.0% - Adjusted EBITDA up organically by 24.8% - Gerresheimer confirms guidance for financial year 2023 Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug ...
Ein DokumentmehrPress release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
Ein DokumentmehrPress release: STADA sustains strong momentum with double-digit sales and profit growth in 2022
Ein DokumentmehrInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
Ein DokumentmehrPress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
Ein DokumentmehrPress release: STADA appoints Boris Döbler as Chief Financial Officer
Ein DokumentmehrPress release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
Ein DokumentmehrGerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
Düsseldorf (ots) - At today’s Capital Markets Day, Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirmed its growth agenda and increased its revenue and adjusted ...
Ein DokumentmehrPress release: Stéphane Jacqmin joins STADA from Sanofi and becomes Head of Emerging Markets
Ein DokumentmehrPress release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...
Ein DokumentmehrGerresheimer reports double digit growth in revenue and earnings for the third quarter
Duesseldorf (ots) - - Organic revenue growth of 17.4% in the third quarter supported by continued strong demand for High Value Solutions - Organic adjusted EBITDA up 13.3% - Gerresheimer firmly on track to deliver on FY 2022 guidance Gerresheimer AG, a leading provider of healthcare & beauty solutions ...
Ein DokumentmehrPress release: STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease
STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease - Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A ...
Ein DokumentmehrPress release: Strong in-market performance leads STADA to double-digit growth
Strong in-market performance leads STADA to double-digit growth - Continued strong organic market-share gains across key European markets, supported by several launches - Adjusted Group sales advance by 15% while adjusted EBITDA improve by 23% in first half of 2022 - STADA CEO Peter Goldschmidt: “In ...
Ein DokumentmehrPress release: STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy - The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a ...
Ein DokumentmehrGerresheimer on track to deliver record financial year 2022 after solid second quarter
Ein DokumentmehrPress release: STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab - Offers a comprehensive range of presentations to the EU adalimumab biosimilars market - Adalimumab marks the first molecule ...
Ein DokumentmehrPress release: STADA set to expand Specialty portfolio after positive CHMP opinion on Kinpeygo orphan medicine for IgA nephropathy
STADA set to expand Specialty portfolio after positive CHMP opinion on KinpeygoTM orphan medicine for IgA nephropathy - CHMP within the European Medicines Agency issues positive opinion on KinpeygoTM, a novel oral formulation of budesonide, for ...
Ein DokumentmehrBrenntag’s Pharma section signs exclusive agreement for health-promoting product line Akovita ELIP in EMEA
Ein Dokumentmehr- 2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
Ein Dokumentmehr - 2
COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant
Ein Dokumentmehr - 7
Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021
Ein Dokumentmehr Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins
Ein Dokumentmehr- 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr - 5
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups
Ein Dokumentmehr Fresenius achieves record Q3 earnings - improves 2011 earnings outlook
Bad Homburg (ots) - Q1-3 2011: - Sales EUR 12.1 billion, +2% at actual rates, +5% in constant currency - EBIT EUR 1,862 million, +5% at actual rates, +9% in constant currency - Net income EUR 565 million, +14% at actual rates, +17% in constant currency - Fresenius improves 2011 earnings1 outlook of 15% ...
Ein Dokumentmehr